Coivas review: pricing and terms

What Coivas says

These are attributed first-party merchant statements, not neutral medical evidence:

• Coivas describes the offered medication as compounded semaglutide.¹
• Coivas says a medical consultation with a licensed care provider is required.¹
• Reported introductory monthly equivalent: $119/mo for new GLP-1 users, billed $357 for the first 3 months; not a $119 first checkout charge. The captured selector joins medication names, so use the Challenge page for medication-specific context. Coivas Challenge reports quarterly semaglutide at $119/mo then $149/mo, and quarterly tirzepatide at $199/mo then $229/mo. Introductory pricing is limited to new GLP-1 users and the first billing cycle. Monthly equivalents are not monthly billing.¹

Reported pricing and subscription terms

Reported introductory monthly equivalent: $119/mo for new GLP-1 users, billed $357 for the first 3 months; not a $119 first checkout charge. The captured selector joins medication names, so use the Challenge page for medication-specific context. Coivas Challenge reports quarterly semaglutide at $119/mo then $149/mo, and quarterly tirzepatide at $199/mo then $229/mo. Introductory pricing is limited to new GLP-1 users and the first billing cycle. Monthly equivalents are not monthly billing. Coivas reports clinician review included and no separate membership or per-visit fees. Some Services are offered on a subscription basis. By enrolling in a subscription, you authorize us to charge your payment method on a recurring basis at the then-current rate. Prices are subject to change with 30 days' notice. You may cancel your subscription at any time through your account settings or by contacting support. All fees are in U.S. dollars and are non-refundable except as required by law or as expressly stated in our Refund Policy. We do not currently accept insurance; you are responsible for all charges.

What the captured Coivas page can actually establish

Coivas reports clinician review included and no separate membership or per-visit fees. Coivas partners with state-licensed 503A compounding pharmacies and 503B outsourcing facilities to fulfill prescriptions when appropriate. Coivas reports most reviews within 24 hours and typical arrival within a few business days after approval; this is not a guaranteed delivery date. Coivas reports availability in all 50 states; its Terms limit services to states where it is authorized to provide telehealth services. Some Services are offered on a subscription basis. By enrolling in a subscription, you authorize us to charge your payment method on a recurring basis at the then-current rate. Prices are subject to change with 30 days' notice. You may cancel your subscription at any time through your account settings or by contacting support. All fees are in U.S. dollars and are non-refundable except as required by law or as expressly stated in our Refund Policy. We do not currently accept insurance; you are responsible for all charges.

Build a Coivas cost worksheet before entering checkout

Reported introductory monthly equivalent: $119/mo for new GLP-1 users, billed $357 for the first 3 months; not a $119 first checkout charge. The captured selector joins medication names, so use the Challenge page for medication-specific context. Coivas Challenge reports quarterly semaglutide at $119/mo then $149/mo, and quarterly tirzepatide at $199/mo then $229/mo. Introductory pricing is limited to new GLP-1 users and the first billing cycle. Monthly equivalents are not monthly billing. Some Services are offered on a subscription basis. By enrolling in a subscription, you authorize us to charge your payment method on a recurring basis at the then-current rate. Prices are subject to change with 30 days' notice. You may cancel your subscription at any time through your account settings or by contacting support. All fees are in U.S. dollars and are non-refundable except as required by law or as expressly stated in our Refund Policy. We do not currently accept insurance; you are responsible for all charges.

A consultation is a gate, not an outcome promise

Coivas’s consultation language indicates that a care-provider interaction is part of the merchant’s described pathway. It does not promise that a reader qualifies, that semaglutide will be prescribed, that compounded medication is appropriate, or that a particular result will follow. Before relying on the offer, a prospective patient can ask who conducts the consultation, what jurisdiction licenses apply, how follow-up questions are handled, which pharmacy would dispense an approved prescription, and what happens if no prescription is issued. Those are service-clarity questions, not medical advice. Product selection, prescribing, dosing, and monitoring remain matters for a licensed clinician. The practical consumer decision is whether Coivas discloses enough about the pathway and contract to justify proceeding to its consultation—not whether this page can predict treatment suitability or performance.

Pricing and billing

Reported introductory monthly equivalent: $119/mo for new GLP-1 users, billed $357 for the first 3 months; not a $119 first checkout charge. The captured selector joins medication names, so use the Challenge page for medication-specific context. Coivas Challenge reports quarterly semaglutide at $119/mo then $149/mo, and quarterly tirzepatide at $199/mo then $229/mo. Introductory pricing is limited to new GLP-1 users and the first billing cycle. Monthly equivalents are not monthly billing. Coivas reports clinician review included and no separate membership or per-visit fees.¹

Clinician and prescription boundary

Coivas's published consultation requirement does not establish that any reader is eligible or that a prescription will be issued. Eligibility, prescribing, product selection, and treatment decisions belong to a licensed clinician; this review does not provide medical advice or dosing guidance.¹

Compounded-drug and FDA status

The source describes compounded semaglutide, which is distinct from FDA-approved branded semaglutide drugs. Compounded drugs are not FDA approved, and FDA does not premarket-review them for safety, effectiveness, or quality.²

What remains unknown

• Reported introductory monthly equivalent: $119/mo for new GLP-1 users, billed $357 for the first 3 months; not a $119 first checkout charge. The captured selector joins medication names, so use the Challenge page for medication-specific context. Coivas Challenge reports quarterly semaglutide at $119/mo then $149/mo, and quarterly tirzepatide at $199/mo then $229/mo. Introductory pricing is limited to new GLP-1 users and the first billing cycle. Monthly equivalents are not monthly billing.
• Some Services are offered on a subscription basis. By enrolling in a subscription, you authorize us to charge your payment method on a recurring basis at the then-current rate. Prices are subject to change with 30 days' notice. You may cancel your subscription at any time through your account settings or by contacting support. All fees are in U.S. dollars and are non-refundable except as required by law or as expressly stated in our Refund Policy. We do not currently accept insurance; you are responsible for all charges.
• No comparable independent public-review dataset was captured.
• No evidence supports an efficacy promise, outcome guarantee, or individualized recommendation.